Copyright © 2004 by the European Society of Cardiology.
Clinical research
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease
a Department of Medicine, Karolinska Hospital, Stockholm, Sweden
b Department of Cardiovascular Medicine John Radcliffe Hospital, Oxford, UK
c Department of Medicine, University of Montreal, Montreal, Canada
d Department of VA Medical center, Muskogee, Oklahoma, USA
e Division of Cardiology, McMaster University, Hamilton General Hospital, Hamilton, Canada
* Correspondence to: Dr J. B. Östergren, Karolinska Hospital, Division of Emergency Medicine, Department of Medicine, 171 76 Stockholm, Sweden. Tel: +46 8 51775473; Fax: +46 8 318264
E-mail address: jan.ostergren{at}ks.se
Received 25 June 2003; revised 21 October 2003; accepted 29 October 2003
Abstract
Aims The aim of this study was to assess the prognostic importance of peripheral arterial disease (PAD) as evaluated by ankle blood pressure index (ABI), and the impact of ramipril on the prevention of major cardiovascular events in PAD patients included in the Heart Outcomes Prevention Evaluation (HOPE) study.
Methods and results Patients were randomized to treatment with ramipril or placebo and followed for 4.5 years. Ankle brachial blood pressure index was measured, mainly by digital palpation of the foot pulse, at baseline in 8986 patients. The ABI was subnormal (
0.9) in 3099 patients and normal in 5887 patients. A low ABI was a strong predictor of morbidity and mortality during the follow-up even in patients with no clinical symptoms of PAD (n=6769). This was so for the primary outcome of the study; ABI>0.9:13.1%, 0.6–0.9: 18.2% and <0.6: 18.0% (P<0.0001) and for mortality from all causes: in those with a normal ABI it was 8.5%, in those with ABI >0.6–0.9, 12.4% and 14.2% in those with an ABI lower than 0.6 (P<0.0001). Ramipril reduced the risk of clinical outcomes in those with a clinical history of PAD as well as in the patients with subclinical PAD.
Conclusions The ABI even if measured simply by palpation of the foot arteries is a strong predictor for future cardiovascular events and for all-cause mortality. Ramipril prevented major cardiovascular events in patients with clinical as well as subclinical PAD.
Key Words: Blood pressure • Peripheral vascular disease • Cardiovascular diseases • Ankle blood pressure • Risk factors
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- HOPE brings hope for the use of the ankle-brachial index as cardiovascular risk marker
- Daniel Duprez
EHJ 2004 25: 1-2.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  D G Hackam, N M Sultan, and M H Criqui Vascular protection in peripheral artery disease: systematic review and modelling study Heart, July 1, 2009; 95(13): 1098 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Marshall, P. H. Lin, T. T. Huynh, and P. Kougias How Optimal is the Medical Management of Patients Prior to Major Reconstructive Vascular Surgery? The Results of a Cross-sectional Study Vascular and Endovascular Surgery, June 1, 2009; 43(3): 238 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Tavintharan, Ning Cheung, Su Chi Lim, W. Tay, A. Shankar, E. Shyong Tai, and T. Y. Wong Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus Diabetes and Vascular Disease Research, April 1, 2009; 6(2): 80 - 86. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Migliacci, R. Nasorri, P. Ricciarini, and P. Gresele Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease Fam. Pract., August 1, 2008; 25(4): 228 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. H. Feringa, J. J. Bax, S. Hoeks, V. H. van Waning, A. Elhendy, S. Karagiannis, R. Vidakovic, O. Schouten, E. Boersma, and D. Poldermans A Prognostic Risk Index for Long-term Mortality in Patients With Peripheral Arterial Disease Arch Intern Med, December 10, 2007; 167(22): 2482 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G Hackam The ankle brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease Evid. Based Med., December 1, 2007; 12(6): 187 - 187. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Poredos and B. Jug The Prevalence of Peripheral Arterial Disease in High Risk Subjects and Coronary or Cerebrovascular Patients Angiology, July 1, 2007; 58(3): 309 - 315. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. DeLoach and E. R. Mohler III Peripheral Arterial Disease: A Guide for Nephrologists Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 839 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G Hackam and J. W Eikelboom Antithrombotic treatment for peripheral arterial disease Heart, March 1, 2007; 93(3): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Schofield, G. Libby, G. M. Brennan, R. R. MacAlpine, A. D. Morris, G. P. Leese, and for the DARTS/MEMO Collaboration Mortality and Hospitalization in Patients After Amputation: A comparison between patients with and without diabetes Diabetes Care, October 1, 2006; 29(10): 2252 - 2256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Beckman, M. R. Jaff, and M. A. Creager The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit? Circulation, August 22, 2006; 114(8): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Golomb, T. T. Dang, and M. H. Criqui Peripheral Arterial Disease: Morbidity and Mortality Implications Circulation, August 15, 2006; 114(7): 688 - 699. [Full Text] [PDF]
|
|
|
|
|
|
T. W. Rice and A. B. Lumsden Optimal Medical Management of Peripheral Arterial Disease Vascular and Endovascular Surgery, August 1, 2006; 40(4): 312 - 327. [Abstract] [PDF]
|
|
|
|
 |
|
 E. P Brass and W. R Hiatt Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies Vascular Medicine, August 1, 2006; 11(3): 141 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 H. H.H. Feringa, V. H. van Waning, J. J. Bax, A. Elhendy, E. Boersma, O. Schouten, W. Galal, R. V. Vidakovic, M. J. Tangelder, and D. Poldermans Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R Hiatt and M. J Krantz Masterclass series in peripheral arterial disease: Antiplatelet therapy for peripheral arterial disease and claudication Vascular Medicine, February 1, 2006; 11(1): 55 - 60. [Abstract] [PDF]
|
|
|
|
|
|
A. M. O'Hare, A. B. Newman, R. Katz, L. F. Fried, C. O. Stehman-Breen, S. L. Seliger, D. S. Siscovick, and M. G. Shlipak Cystatin C and Incident Peripheral Arterial Disease Events in the Elderly: Results From the Cardiovascular Health Study Arch Intern Med, December 12, 2005; 165(22): 2666 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Murabito, J. C. Evans, R. B. D'Agostino Sr., P. W. F. Wilson, and W. B. Kannel Temporal Trends in the Incidence of Intermittent Claudication from 1950 to 1999 Am. J. Epidemiol., September 1, 2005; 162(5): 430 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gresele and R. Migliacci Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur. Heart J., October 2, 2004; 25(20): 1769 - 1771. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor Mayo Clin. Proc., September 1, 2004; 79(9): 1107 - 1109. [PDF]
|
|
|
|
|
|
D. Duprez HOPE brings hope for the use of the ankle-brachial index as cardiovascular risk marker Eur. Heart J., January 1, 2004; 25(1): 1 - 2. [Full Text] [PDF]
|
|